In this video, health care analysts David Williamson and Max Macaluso discuss Vertex's recent tie up with two deep-pocketed members of big pharma. Although Vertex currently owns the standard of care for hepatitis C treatments, it isn't sitting on its laurels. Watch and find out what this new deal means for Vertex, its partners, and its competitors.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Vertex's New Big Pharma Partners
NASDAQ: VRTX
Vertex Pharmaceuticals

A new potential hep-c drug combo takes shape
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
David Williamson owns shares of Johnson & Johnson. The Motley Fool owns shares of Gilead Sciences, GlaxoSmithKline, and Johnson & Johnson. Motley Fool newsletter services recommend Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, and Vertex Pharmaceuticals. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned





*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.